Shanghai Pharmaceutical plans to acquire Cardinal Health China business from US-based healthcare company Cardinal Health for $1.2bn.
The divestiture will enable the Chinese pharmaceutical company to strengthen its distribution network.
Sapphire I (HK) Holdings has acquired a 49% stake in Chinese pharmaceutical company Hisun-Pfizer Pharmaceuticals from Pfizer.
The divestment enables both Hisun and Pfizer to concentrate on their core businesses.
Sumitomo Corporation of America (SCA) plans to acquire a 20% stake in US-based generic drug manufacturer Sawai America Inc (SAI) from Sawai Pharmaceutical (SPCL) for $211m.
SCA, a subsidiary of Sumitomo Corporation, is a transport and logistics services provider, while SPCL is a generic pharmaceuticals manufacturer.
Both companies involved in the acquisition are based in Japan.
Grupo Biotoscana SL has acquired pharmaceutical manufacturer Laboratorio DOSA S.A. for BRL100m ($30.48m).
The acquisition will enable the specialist therapeutic products developer to expand its product portfolio and geographic reach.
